YSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
General News
On Feb 26th, 2015, the NYS Drug Utilization Review Board (DURB) voted unanimously to move Viekira Pak to preferred status for NYS Medicaid Fee-for-service members, and to remove restrictions based on disease prognosis and severity from the current clinical criteria for Viekira Pa...
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
The Association of Asian Pacific Community Health Organizations (AAPCHO), today launched new a website highlighting stories of Asian Americans and Pacific Islanders (AAPIs) impacted by hepatitis B.The #justB website was created to bring more attention to hepatitis B and the impac...
Intern will work under the supervision of the Director of Program Implementation & Capacity Building in the NYC Department of Health, Viral Hepatitis Surveillance, Prevention & Control Program.
FDA Approves Viekira Pak to Treat Hep C A new hepatitis C medication, Viekira Pak, was approved today by the U.S. Food and Drug Administration (FDA). AbbVie, who markets the drug, has not immediately released the price of the new all-oral Hep C medication which will now rival Ha...
New York state’s Medicaid program spent $193.2 million during the first six months of 2014 on Sovaldi, the controversial Hepatitis C drug that carries an $84,000-per-patient price tag.
Olysio has been approved by the FDA, in combination with Sovaldi, for the treatment of Hepatitis C. It is substantially more expensive than Harvoni; although it depends on treatment time, a 12-week Harvoni treatment costs $94,500, compared to the Olysio-Sovaldi 12-week tag of $1...
Literature surrounding the burden of and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in persons with tuberculosis (TB) disease remains limited and focused on populations outside the USA.
Seeking Personal Stories About Living With Hepatitis C Remedy Health Media, creator of the Live Bold Live Now initiative, works to empower patients and caregivers with the information and applications needed to efficiently navigate the healthcare landscape and as a result, to p...
